直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 119067
著者
板東, 浩 Tokushima University|Medical Research|Integrative Medicine Japan KAKEN研究者をさがす
キーワード
Imeglimin (Twymeeg)
Oral hypoglycemic agent (OHA)
Trials of IMeglimin for Efficacy and Safety (TIMES)
Mitochondrial morphology
Lactic acidosis
資料タイプ
学術雑誌論文
抄録
A novel imeglimin (Twymeeg) was developed as an oral hypoglycemic agent (OHA) in Japan. It has clinically dual action for increasing insulin secretion and reducing insulin resistance, from Trials of IMeglimin for Efficacy and Safety (TIMES) 1-3. For basic medicine, imeglimin revealed reduction of apoptotic β-cell death with reduced expression for inflammation. Thus, imeglimin may increase insulin granules, bring beneficial efficacy on β-cell mitochondrial morphology and enhance directly insulin secretion from β-cell of the pancreas. Imeglimin has chemical moiety for metformin. Compared with both agents using experiments of dog and mice, lactic acidosis would be lower in imeglimin group.
掲載誌名
SunText Review of Case Reports & Images
ISSN
27664589
出版者
SunText Reviews
3
4
開始ページ
158
発行日
2022-10-27
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系